Log in Free sign up

SAB Biotherapeutics (SABS) News and press releases

News

From Benzinga Pro

Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $7

News, Price Target, Analyst Ratings

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $10 to $7.

SAB Biotherapeutics Q1 EPS $0.02 Down From $0.05 YoY

SAB Biotherapeutics (NASDAQ:SABS) reported quarterly earnings of $0.02 per share. This is a 60 percent decrease over earnings of $0.05 per share from the same period last year.

51 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.

12 Health Care Stocks Moving In Tuesday's Intraday Session

Intraday Update, Markets, Movers

30 Stocks Moving In Tuesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 139% to $5.40 after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.

Chardan Capital Maintains Buy on SAB Biotherapeutics, Lowers Price Target to $10

News, Price Target, Analyst Ratings

Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and lowers the price target from $17 to $10.

53 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

12 Health Care Stocks Moving In Thursday's Intraday Session

Intraday Update, Movers

36 Stocks Moving In Thursday's Mid-Day Session

News, Intraday Update, Markets, Movers, Trading Ideas

12 Health Care Stocks Moving In Thursday's After-Market Session

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Tuesday's session saw 729 companies set new 52-week lows.

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg

Biotech, Earnings, News, Penny Stocks, Small Cap, Top Stories, General

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (NASDAQ: IBB) retreated in four out of five sessions of the week.

68 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers ECMOHO Limited (NASDAQ: MOHO) climbed 56.7% to close at $0.3650 on Wednesday after jumping 10% on Tuesday.

Mid-Afternoon Market Update: Dow Gains 2%; SAB Biotherapeutics Shares Slide

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining 2% on Wednesday.

12 Health Care Stocks Moving In Wednesday's Intraday Session

Intraday Update, Markets, Movers

41 Stocks Moving In Wednesday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers ECMOHO Limited (NASDAQ: MOHO) jumped 67% to $0.3890 after jumping 10% on Tuesday.

Mid-Day Market Update: Nasdaq Surges 150 Points; US Crude Oil Inventories Fall By 2.6M Barrels

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks extended gains midway through trading, with the Nasdaq index jumping 150 points on Wednesday.

Stocks That Hit 52-Week Lows On Wednesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 107 companies set new 52-week lows.

Mid-Morning Market Update: U.S. Stocks Mixed; Dollar Tree Reports Mixed Q4 Results

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks opened mixed this morning, with the Dow Jones adding more than 200 points on Wednesday.

NIH Discontinues COVID-19 Phase 3 Trial Assessing SAB Biotherapeutics' SAB-185

Biotech, News, Penny Stocks, Health Care, General

Press releases

From Benzinga Pro

SAB Biotherapeutics Provides Company Update for Q1 2022 Financial Results

Earnings, Press Releases

Full data from Phase 2a trial that evaluated SAB-176 for treatment of seasonal influenza expected third quarter 2022 – first clinical data set from novel platform Phase 2 data for SAB-185 expected to be available later

SAB Biotherapeutics to Present at 2022 H.C. Wainwright Global Investment Conference

News, Press Releases

SIOUX FALLS, S.D., May 12, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (NASDAQ:SABS), announced today its participation at the H.C. Wainwright Global Investment Conference, which takes place May 23-26, 2022. As part

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

Earnings, Press Releases

SAB executing on its strategy to build a proprietary immune and autoimmune disorders pipeline, including respiratory diseases that affect immunocompromised patients Plans to announce full data from Phase 2a trial

SAB Biotherapeutics Announces Publication of Nonclinical Data Demonstrating SAB-185 Has High Potency for Effectively Neutralizing Circulating and Emerging SARS-CoV-2 Variants

Health Care, Press Releases

In the FDA-conducted study, SAB-185 consistently demonstrated high avidity and high potency for effectively neutralizing a broad range of SARS-CoV-2 strains and variants through Delta SAB-185 additionally outperformed

SAB Biotherapeutics Announces Update to the Phase 3 NIH ACTIV-2 Trial Design Evaluating SAB-185 for Treatment of COVID-19

Press Releases, General

ACTIV-2 Phase 3 trial continuing as placebo-controlled study in Omicron variant COVID participants SIOUX FALLS, S.D., Feb. 25, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (SAB) (NASDAQ:SABS), a clinical-stage